VPC-70619 |
| Catalog No.GC64562 |
VPC-70619 es un potente inhibidor de N-Myc activo por vÍa oral. VPC-70619 bloquea el heterocomplejo N-Myc-Max para que no se una a las cajas E de ADN y demostrÓ una fuerte actividad de inhibiciÓn contra las lÍneas celulares dependientes de N-Myc, asÍ como una alta biodisponibilidad tanto en la administraciÓn oral como intraperitoneal.
Products are for research use only. Not for human use. We do not sell to patients.
Cas No.: 2361742-30-3
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
VPC-70619 is a potent, orally active N-Myc inhibitor. VPC-70619 blocks the N-Myc-Max heterocomplex from binding to DNA E-boxes and demonstrated strong inhibition activity against N-Myc-dependent cell lines as well as high bioavailability in both oral and intraperitoneal administration[1].
[1]. Ton AT, et al. Development of VPC-70619, a Small-Molecule N-Myc Inhibitor as a Potential Therapy for Neuroendocrine Prostate Cancer. Int J Mol Sci. 2022;23(5):2588. Published 2022 Feb 26.
Average Rating: 5 (Based on Reviews and 30 reference(s) in Google Scholar.)
GLPBIO products are for RESEARCH USE ONLY. Please make sure your review or question is research based.
Required fields are marked with *